LGALS3 and breast carcinoma: It has been reported that binding of galectin-3 to mucin 1 (MUC1) could promote tumor cell malignancy [22] and the cell surface interaction of annexin A2 and galectin-3 could also modulate epidermal growth factor receptor signaling in epidermal growth factor receptor-2 (Her-2) negative breast cancer cells [23].